Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Health Care Overhaul Ignores Illegal Immigrants
"As Congress wrangles with overhauling the health care system, there is one population not being discussed. No proposal for a national health plan would cover the nation"s estimated 11 million illegal immigrants," NPR reports. But "analysts say the notion that illegal immigrants drain the health system is overblown. Simply figuring out how many undocumented immigrants lack insurance is not easy," although the Lewin Group has estimated that the number is about 6.1 million, which is "only about half the total population of undocumented immigrants." John Sheils of the Lewin Group "says many illegal immigrants use false documents to work on the books, with regular tax deductions and benefits."
generic viagra online
Preseason Shoulder Strength May Determine Injury Severity For Baseball Pitchers
Athletic injuries can derail any player"s ability to compete, but for a baseball pitcher his shoulder strength and control is critical. A new study to be presented at the American Orthopaedic Society for Sports Medicine"s (AOSSM) Annual Meeting in Keystone, Colorado, suggests that testing a pitcher"s shoulder strength through a series of exercises during the preseason may help create a focused strength training program to prevent serious injury during the season.
News of the day
Covidien Announces Health Canada Approval For Its Generic Myocardial Perfusion Imaging Kit
Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Health Canada has approved the Company"s Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien"s generic product is fully substitutable for Cardiolite®, a myocardial perfusion imaging agent used for detecting coronary artery disease.
Mental Health

Biovista Inc. Announces Positive Efficacy Results In A Pre-Clinical Trial Of Its BVA-601 Repositioned Drug For Epilepsy

Biovista Inc. announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid. "We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies," said Aris Persidis, Ph.D., President of Biovista. "This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company," added Dr. Persidis. Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures may be transient signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Epilepsy is one of the world"s oldest recognized conditions, affecting around 50 million people worldwide. Fear, discrimination and social stigma have surrounded epilepsy for centuries. Some of the stigma continues today in many countries impacting the quality of life of people with the disorder. In the animal proof of concept trial, BVA-601 was compared to diazepam, a potent anti-epileptic drug that is efficient in reducing epileptic activity but has troubling adverse events. BVA-601 induced a statistically significant reduction in the number of animals showing epileptic activity and delayed the onset of epileptic seizures. About Biovista"s repositioning pipeline and technology platform Biovista applies high-efficiency discovery efforts to finding solutions for commercially relevant unmet medical needs. Biovista"s proprietary repositioning technology allows it to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and short time spans. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and autoimmune diseases. Biovista Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009